Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway
Scinai Immunotherapeutics CEO Amir Reichman issued a shareholder letter detailing growth in the company's CDMO business and an extended operating runway following recent financing.
Stocks · News reference
Scinai Immunotherapeutics Regains Nasdaq Compliance
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closedJERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Scinai Immunotherapeutics shares are trading lower after the company announced the closing of a $4 million financing through a private placement and warrant exercise transactions.
Scinai Immunotherapeutics shares are trading lower after the company announced a $4 million private placement and warrant inducement transaction.
Scinai Immunotherapeutics Announces ~$4M Financing Via $1.20/ADS Private Placement And Warrant Inducement Repricing April 2026 Warrants To $1.20/ADS
Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?
Scinai Immunotherapeutics stock jumped 27% after securing a $5.1M biopharma manufacturing deal. Details on SCNI's major contract win.
Scinai Immunotherapeutics shares are trading higher after the company announced a development and manufacturing agreement with a biopharma company, boosting committed customer orders to $7.6 million, up 300% from year-end 2025.